{"schema_version":"secwatch.filing_event.v1","accession":"0000896622-26-000090","form_type":"8-K","ticker":"ATR","cik":"0000896622","company_name":"APTARGROUP, INC.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.905355+00:00","generated_at":"2026-05-15T01:26:31.258018+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aptar Q1 adjusted EPS $1.19 (-8% YoY); names Gael Touya CEO effective Sept 1","bullets":["Reported sales up 11% to $982.9M; core sales flat; net income down 8% to $73M.","Adjusted EPS $1.19 vs. $1.30; adjusted EBITDA margin 19.2% vs. 20.7%.","Pharma core sales -1% (prescription -10% on emergency medicine destocking; injectables +20%).","Beauty core sales +3%; Closures core flat; both segments saw margin compression.","Q2 2026 adjusted EPS guidance $1.32-$1.40; declared $0.48 dividend payable May 27."],"urls":{"canonical":"https://secwatch.observer/filing/0000896622-26-000090","json":"https://secwatch.observer/filing/0000896622-26-000090.json","markdown":"https://secwatch.observer/filing/0000896622-26-000090.md","text":"https://secwatch.observer/filing/0000896622-26-000090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896622/000089662226000090/0000896622-26-000090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896622/000089662226000090/atr-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:26:31.258018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"858e255fc75bb4cb3cdc3a7b5161bc48c811bf54","claim":"APTARGROUP, INC. reported the quarter ended March 31, 2026 results: revenue $982.9 million, net income $73 million, EPS $1.12. Guidance initiated.","evidence_excerpt":"fragrance and beverage applications,” said Stephan B. Tanda, Aptar President and CEO. First Quarter Results For the quarter ended March 31, 2026, reported sales increased 11% to $982.9 million compared to $887.3 million in the prior year period. Core sales were flat compared to the prior year period. First Quarter Segment Sales Analysis (Change Over Prior Year) Pharma","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/896622/000089662226000090/0000896622-26-000090-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"$982.9 million"},{"label":"Net income","value":"$73 million"},{"label":"EPS","value":"$1.12"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}